Skip to main content

Table 1 Heparin-free MARS studies

From: A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System

Study Design Indication Total
n
Heparin Free
patients/sessions
Clotting
n (P/S %)
Coagulopathy or Bleeding
n (P/S %)
References
Doria et al. (2004) retrospective AoCLF/pruritus 9 9/74 0 (0/0%) 4 (44/nd%) [6]
Tan et al. (2007)a retrospective ALF/AoCLF 4 4/12 1 (25/8%) 1 (25/8%) [8]
Bachli et al. (2007) retrospective ALF/AoCLF/pruritus 21 nd/40 nd 7 (nd/18%) [7]
Yang et al (2008)a retrospective ALF/AoCLF 10 5/13 1 (20/8%) 1 (20/8%) [9]
Tan et al. (2010)a retrospective ALF/AoCLF 12 12/44 11 (nd/25%) 4 (nd/9%) [10]
Faybik et al.(2011) Prospective ALF/AoCLF 20 20/77 1 (5/1%) 1 (5/1%) [15]
  1. aThese papers originate from the same research group. It is unclear whether these manuscripts report on the same patient population or not. ALF, acute liver failure; AoCLF, acute-on-chronic liver failure; MARS, Molecular Adsorbents Recirculation System; P, patients; S, sessions; nd, no data.